专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009127922A2 PHARMACEUTICAL FORMULATION FOR TREATING CARDIOVASCULAR DISEASE 审中-公开
标题翻译：用于治疗心血管疾病的药物制剂
公开(公告)号：WO2009127922A2
公开(公告)日：2009-10-22
申请号：PCT/IB2009000331
申请日：2009-02-23
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , PARK SUN WOO , JANG SEOK YOUNG , LEE SANG JU , JO YOUNG GWAN , LEE JUN YOUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , PARK SUN WOO , JANG SEOK YOUNG , LEE SANG JU , JO YOUNG GWAN , LEE JUN YOUNG
IPC分类号： A61K9/52 , A61K9/22 , A61K9/28 , A61K31/44 , A61K47/38 , A61P9/00
CPC分类号： A61K31/44 , A61K9/209
摘要： The present invention provides a pharmaceutical formulation containing an immediate-release compartment and an extended-release compartment. The immediate-release compartment comprises a statin lipid-lowering drug, its isomer, or its pharmaceutically acceptable salt as a pharmacologically active ingredient and the extended-release compartment contains a dihydropyridine calcium channel blocker, its isomer, or its pharmaceutically acceptable salt as a pharmacologically active ingredient. The combined formulation of immediate-release, statin lipid-lowering drug and extended-release dihydropyridine calcium channel blocker, is pharmacologically, clinically, scientifically, and economically more useful than the single formulation of each of the drugs or a simple combination of the drugs, in preventing and treating cardiovascular disease, cardiopulmonary disease, pulmonary disease, or kidney disease in patients with metabolic syndrome and insulin resistance and patients with diabetes or suspected prediabetes. médicamentsThe formulation of the present invention allows different release times for the statin lipid-lowering drug and the dihydropyridine calcium channel blocker, and thus prevents mutual antagonism and side effects between the two drugs, and provides easy administration for patients simultaneously taking the two drugs simultaneously.
摘要翻译：本发明提供了含有速释隔室和缓释隔室的药物制剂。速释隔室包含作为药理活性成分的他汀类降脂药，其异构体或其药学上可接受的盐，并且缓释室包含二氢吡啶类钙通道阻断剂，其异构体或其药学上可接受的盐，作为药理学有效成分。速释他汀类降脂药和缓释二氢吡啶钙通道阻滞剂的组合制剂在药理学，临床，科学和经济上比每种药物的单一制剂或药物的简单组合更有用，用于预防和治疗代谢综合征和胰岛素抵抗患者中的心血管疾病，心肺疾病，肺病或肾病以及糖尿病或怀疑前驱糖尿病患者。本发明的制剂允许他汀类降脂药和二氢吡啶类钙通道阻滞剂的释放时间不同，从而防止两种药物之间的相互拮抗和副作用，并且为同时服用两种药物的患者提供了容易的给药。

2. 发明申请

WO2012032029A1 METHOD FOR RAPID PREPARATION OF SUITABLE [18F]FLUORIDE FOR NUCLEOPHILIC [18F]FLUORINATION. 审中-公开
标题翻译：用于快速制备适用于[18F]荧光的适用[18 F]氟化物的方法。
公开(公告)号：WO2012032029A1
公开(公告)日：2012-03-15
申请号：PCT/EP2011/065366
申请日：2011-09-06
申请人： BAYER PHARMA AKTIENGESELLSCHAFT , CHI, Dae Yoon , LEE, Byoung Se , LEE, Sang Ju , RYU, Jin-Sook , OH, Seung Jun
发明人： CHI, Dae Yoon , LEE, Byoung Se , LEE, Sang Ju , RYU, Jin-Sook , OH, Seung Jun
IPC分类号： A61K51/04 , C07B59/00 , C08F8/44
CPC分类号： C07B59/005 , A61K51/0406 , A61K51/0448 , A61K51/0453 , A61K51/0491 , B01J41/14 , B01J47/022 , B01J49/40 , B01J49/57 , B01J49/60 , C07B59/00 , C07B59/001 , C07B59/002 , C08F8/44 , C08F12/26 , C08F12/32 , C08F212/14 , C08F212/36
摘要： The invention generally relates to the preparation of 18 F-!abeled radiopharmaceuticals. In particular, this invention relates to the advanced processes for an efficient eiution of [ 18 F]fluoride trapped in a cartridge filled with quaternary ammonium polymer which comprises inert non-basic and non-nucleophilic counter anions. The said methods and polymer cartridges allow the rapid preparation of suitable [ 18 F]fiuoride solution, which is also less basic to reduce the formation of byproducts, finally to increase radiochemical yield and purity of 18 F-radiopharmaceuticals.
摘要翻译：本发明一般涉及18F-放射性药物的制备。特别地，本发明涉及一种用于高效吹扫捕集在填充有季铵聚合物的筒中的[18 F]氟化物的先进方法，其包含惰性非碱性和非亲核反阴离子。所述方法和聚合物盒允许快速制备合适的[18 F]氟化物溶液，其也减少副产物形成的碱性，最终提高18F放射性药物的放射化学产率和纯度。

3. 发明申请

WO2009127974A3 PHARMACEUTICAL FORMULATION FOR TREATING CARDIOVASCULAR DISEASE 审中-公开
标题翻译：用于治疗心血管疾病的药物制剂
公开(公告)号：WO2009127974A3
公开(公告)日：2010-03-25
申请号：PCT/IB2009006277
申请日：2009-02-23
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , PARK SUN WOO , JANG SEOK YOUNG , LEE SANG JU , JO YOUNG GWAN , LEE JUN YOUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , PARK SUN WOO , JANG SEOK YOUNG , LEE SANG JU , JO YOUNG GWAN , LEE JUN YOUNG
IPC分类号： A61K9/52 , A61K9/22 , A61K9/28 , A61K31/40 , A61K31/44 , A61K47/38 , A61P9/00 , A61P13/12
CPC分类号： A61K31/44 , A61K9/209
摘要： The present invention provides a pharmaceutical formulation comprising: an early release portion comprising as a pharmaceutical active ingredient a statin-based hypolipidic agent, an isomer thereof, or a pharmaceutically acceptable salt thereof; and a slow release portion comprising as a pharmaceutical active ingredient a dihydropyridine-based calcium channel blocking agent, an isomer thereof, or a pharmaceutically acceptable salt thereof. When compared with a single formulation of each of the drugs or a simple combination formulation of the drugs, the pharmaceutical formulation according to the present invention comprising an early release portion comprising a statin-based hypolipidic agent and a slow release portion comprising a dihydropyridine-based calcium channel blocking agent is pharmaceutically, scientifically, and economically very useful in preventing or treating cardiovascular disease, pulmonary heart disease, pulmonary disease, or kidney disease of patients who have a metabolic syndrome, insulin resistance, diabetes, or prediabetes. The formulation of the present invention is effective in preventing antagonistic and side effects between the drugs by making the dissolution rate of the statin-based hypolipidic agent different from that of the dihydropyridine-based calcium channel blocking agent, and in facilitating patient compliance in taking the drugs by administering the two different drugs simultaneously.
摘要翻译：本发明提供一种药物制剂，其包含：早期释放部分，其包含作为药物活性成分的基于他汀类的降血糖剂，其异构体或其药学上可接受的盐; 以及缓释部分，其包含基于二氢吡啶的钙通道阻断剂，其异构体或其药学上可接受的盐作为药物活性成分。当与药物的单一制剂或药物的简单组合制剂相比时，根据本发明的药物制剂包含早期释放部分，其包含基于他汀类的降血脂药和包含基于二氢吡啶的缓释部分钙通道阻断剂在预防或治疗具有代谢综合征，胰岛素抵抗，糖尿病或糖尿病前期的患者的心血管疾病，肺心病，肺部疾病或肾脏疾病方面在药学，科学和经济上非常有用。本发明的制剂通过使基于他汀类的降血糖剂与二氢吡啶类钙通道阻断剂的溶解速率不同而使药物的拮抗作用和副作用有效，并且为了便于患者服用药物同时服用两种不同药物。

4. 发明申请

WO2009127372A1 PURIFICATION STRATEGY FOR DIRECT NUCLEOPHILIC PROCEDURES 审中-公开
标题翻译：直接核子程序的纯化策略
公开(公告)号：WO2009127372A1
公开(公告)日：2009-10-22
申请号：PCT/EP2009/002674
申请日：2009-04-09
申请人： BAYER SCHERING PHARMA AKTIENGESELLSCHAFT , CYR, John , SRINIVASAN, Ananth , BERNDT, Mathias , GRAHAM, Keith , CHI, Dae, Yoon , LEE, Byoung, Se , CHU, So, Young , LIM, Song-Yi , LEE, Sang, Ju , RYU, Jin-Sook , OH, Seung, Jun
发明人： CYR, John , SRINIVASAN, Ananth , BERNDT, Mathias , GRAHAM, Keith , CHI, Dae, Yoon , LEE, Byoung, Se , CHU, So, Young , LIM, Song-Yi , LEE, Sang, Ju , RYU, Jin-Sook , OH, Seung, Jun
IPC分类号： C07B59/00 , C07B63/02
CPC分类号： C07B63/02 , C07B59/00 , C07B59/001 , C07B2200/11
摘要： The present invention provides novel and advantageous processes for preparing and purifying chemical compounds such as pharmaceuticals. The processes comprise a nucleophilic substitution reaction with a moiety X wherein the leaving group L of a substrate S in the reaction is covalently attached to a purification moiety M. This concept offers a convenient and time-saving way to purify the desired product S-X from non-reacted precursors S-L-M and by-products L-M.
摘要翻译：本发明提供了制备和纯化化合物如药物的新颖且有利的方法。该方法包括与部分X的亲核取代反应，其中反应中的底物S的离去基团L共价连接到纯化部分M.该概念提供了一种方便和省时的方法，以从非极性纯化所需产物SX - 前体SLM和副产物LM。

5. 发明申请

WO2012165799A2 UNDERWATER CAPILLARY TUBE PLASMA DEVICE HAVING GAS CHANNEL 审中-公开
标题翻译：具有气体通道的水下毛细管等离子体装置
公开(公告)号：WO2012165799A2
公开(公告)日：2012-12-06
申请号：PCT/KR2012004073
申请日：2012-05-23
申请人： KOREA BASIC SCIENCE INST , HONG YONG CHEOL , KIM YE JIN , LEE SANG JU , LEE BONG JU
发明人： HONG YONG CHEOL , KIM YE JIN , LEE SANG JU , LEE BONG JU
IPC分类号： C02F1/467 , C02F1/46 , C02F1/72 , H05H1/24
CPC分类号： H05H1/48 , C02F1/4608 , C02F2303/04 , C02F2305/02 , H05H2001/483 , H05H2245/1225
摘要： Disclosed is an underwater capillary tube plasma device having a gas channel. According to one embodiment of the present invention, an underwater capillary tube plasma device comprises: a power supply unit which supplies power; a discharge electrode which receives power supplied from said power supply unit, and induces a capillary tube plasma discharge inside a fluid; and a gas supply unit which injects auxiliary gas into said discharge electrode. According to the embodiments of the present invention, since a gas channel is equipped in an underwater capillary tube plasma discharge electrode, various chemical reactive species are created according to the injected gas, including plasma species which are created from water decomposition caused by a plasma discharge, whereby underwater pollutants are effectively removed. In addition, if the gas is injected like in the present invention, the concentration and the lifetime, within a fluid, of the reactive species which are created by the plasma discharge are increased such that a purification effect by plasma can be maximized. Further, if such auxiliary gas is supplied, plasma can be generated even by a lower power supply compared with when the gas is not injected, thereby reducing energy consumption for fluid purification.
摘要翻译：公开了一种具有气体通道的水下毛细管等离子体装置。根据本发明的一个实施例，一种水下毛细管等离子体装置包括：供电单元，其供电; 放电电极，其接收从所述电源单元供给的电力，并且在流体内引发毛细管等离子体放电; 以及将辅助气体注入到所述放电电极中的气体供给单元。根据本发明的实施例，由于在水下毛细管等离子体放电电极中设置有气体通道，因此根据注入的气体产生各种化学反应性物质，包括由等离子体物质形成的等离子体物质从而有效地去除水中的污染物。此外，如同本发明那样喷射气体，由等离子体放电产生的反应性物质的流体内的浓度和寿命增加，从而能够最大限度地提高等离子体的净化效果。此外，如果供给这种辅助气体，则与不注入气体相比，即使通过较低的电源也能够产生等离子体，从而降低流体净化的能量消耗。

6. 发明申请

WO2011006610A1 NON-POLAR AND POLAR LEAVING GROUPS 审中-公开
标题翻译：非极性和极性组合
公开(公告)号：WO2011006610A1
公开(公告)日：2011-01-20
申请号：PCT/EP2010/004111
申请日：2010-07-06
申请人： BAYER SCHERING PHARMA AKTIENGESELLSCHAFT , GRAHAM, Keith , BERNDT, Mathias , CHI, Dae, Yoon , LEE, Byoung, Se , SHINDE, Sandip, S. , KIL, Hee, Seup , LEE, Sang, Ju , RYU, Jin-Sook , OH, Seung, Jun
发明人： GRAHAM, Keith , BERNDT, Mathias , CHI, Dae, Yoon , LEE, Byoung, Se , SHINDE, Sandip, S. , KIL, Hee, Seup , LEE, Sang, Ju , RYU, Jin-Sook , OH, Seung, Jun
IPC分类号： C07B59/00 , C07D237/16 , C07D405/04 , C07D405/12 , C07D471/08 , C07D213/643
CPC分类号： C07B59/00 , C07C309/73 , C07C2601/14 , C07D213/643 , C07D237/16 , C07D405/04 , C07D405/12 , C07D471/08
摘要： The present invention provides novel and advantageous processes for preparing and purifying pharmaceuticals The processes comprise a nucleophilic reaction wherein a modified leaving group L M , which has increased lipophilicity, of a vector in a nucleophilic reaction which offers a convenient and time-saving way to purify the product from non-reacted precursors vector-L M and by-products L M .
摘要翻译：本发明提供了用于制备和纯化药物的新颖和有利的方法。该方法包括亲核反应，其中亲核反应中载体具有增加的亲脂性的改进的离去基团LM，其提供了方便和省时的方法来纯化来自未反应的前体载体-ML和副产物LM的产物。

7. 发明申请

WO2010082785A3 ORAL PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：口服药物组合物
公开(公告)号：WO2010082785A3
公开(公告)日：2010-11-25
申请号：PCT/KR2010000268
申请日：2010-01-15
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , JANG SEOK YOUNG , LEE SANG JU
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , JANG SEOK YOUNG , LEE SANG JU
IPC分类号： A61K31/44 , A61K9/22 , A61K31/401 , A61K31/505 , A61P1/00
CPC分类号： A61K31/505 , A61K9/20 , A61K31/401 , A61K31/44
摘要： Provided is an oral pharmaceutical composition comprising: a drug which is metabolised in the liver and a liver protectant. The composition of the present invention can prevent or alleviate drug-induced hepatotoxicity following the administration of a drug which is metabolised in the liver.
摘要翻译：提供一种口服药物组合物，其包含：在肝脏中代谢的药物和肝保护剂。本发明的组合物可以在施用在肝脏中代谢的药物后，预防或缓解药物诱发的肝毒性。

8. 发明申请

WO2010047559A3 SUSTAINED-RELEASE PHARMACEUTICAL FORMULATIONS 审中-公开
标题翻译：持续释放药物制剂
公开(公告)号：WO2010047559A3
公开(公告)日：2010-07-29
申请号：PCT/KR2009006157
申请日：2009-10-23
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , JANG SEOK YOUNG , LEE SANG JU
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , JANG SEOK YOUNG , LEE SANG JU
IPC分类号： A61K9/52 , A61K9/14 , A61K9/24 , A61K31/138 , A61K31/192
CPC分类号： A61K9/20
摘要： The present invention relates to sustained-release pharmaceutical formulations comprising beta-adrenergic blockers and HMG-CoA reductase inhibitors. The pharmaceutical formulations of the present invention are more effective, and may reduce side effects when the beta-adrenergic blockers and HMG-CoA reductase inhibitors are individually and simultaneously taken as a single formulation. The pharmaceutical formulations of the present invention are effective for treating hypertension in patients with complex diseases such as hyperlipidemia, coronary artery disease, etc. The pharmaceutical formulations of the present invention are also effective for preventing complications developed from the abovementioned diseases, and make it easy to give administration instructions to patients.
摘要翻译：本发明涉及包含β-肾上腺素能阻断剂和HMG-CoA还原酶抑制剂的持续释放药物制剂。当β-肾上腺素能阻断剂和HMG-CoA还原酶抑制剂单独和同时作为单一制剂使用时，本发明的药物制剂更有效，并且可以减少副作用。本发明的药物制剂对于治疗具有诸如高脂血症，冠状动脉疾病等复杂疾病的患者的高血压是有效的。本发明的药物制剂对于预防由上述疾病产生的并发症也是有效的，并且使其容易向患者提供管理指导。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式